Knowledge Hub

Seasonal Influenza Therapeutics in Asia-Pacific Market worth $1.71 Billion by 2022

Press Release   •   Feb 03, 2017 05:33 EST

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers. Continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

View Report @

GBI Research’s analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. GBI Research expects that quadrivalent seasonal influenza vaccines will replace their trivalent vaccines forerunner by the end of the forecast period.


The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%.

Trivalent and quadrivalent vaccines dominate the seasonal influenza market, but unmet needs exist in terms of safety and efficacy.

  • Will the drugs under development fulfill the unmet needs of the seasonal influenza market?
  • Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies?
  • How will available therapies be affected by upcoming pipeline therapies?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in seasonal influenza.

  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline drugs fulfill the unmet needs of seasonal influenza market?

Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of quadrivalent therapies.

  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

Various drivers and barriers will influence the market over the forecast period.

  • What barriers limit the uptake of premium-priced vaccines in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Get Sample Copy Of This Report @

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the seasonal influenza market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the seasonal influenza pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict seasonal influenza market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the seasonal influenza deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 9

2.1 Disease Introduction 10

2.2 Epidemiology 10

2.3 Symptoms 12

2.4 Etiology and Pathophysiology 13

2.4.1 Pathophysiology 14

2.5 Diagnosis 14

2.6 Prognosis 16

2.7 Treatment Options 17

2.7.1 Treatment Algorithm 17

2.7.2 Pharmacological Treatments 19

2.7.3 Non-pharmacological Treatments 21

2.7.4 Exercise 21

2.7.5 Dietary Interventions 22

3 Marketed Products 23

3.1 Overview 23

3.2 Fluarix Tetra - GlaxoSmithKline 23

3.3 FluQuadri - Sanofi Pasteur 25

3.4 Vaxigrip - Sanofi Pasteur 25

3.5 Agrippal - CSL 26

3.6 Fluad - CSL 27

3.7 Fluvax/Afluria - CSL 27

3.8 Optaflu - CSL 28

3.9 Influvac - Abbott 29

3.10 GC Flu - Green Cross Corporation 29

3.11 Intanza/IDflu - Sanofi Pasteur 30

3.12 SkyCellflu - SK Chemicals 31

3.13 Nasovac-S - Serum Institute of India 31

3.14 Comparative Efficacy and Safety of Marketed Products 32

4 Pipeline Analysis 34

4.1 Overview 34

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 35

4.3 Pipeline by Molecular Target 37

4.4 Promising Pipeline Candidates 39

4.4.1 VN-100 - Daiichi Sankyo 39

4.4.2 ASP7374 (UMN-0502) - UMN Pharma 41

4.4.3 MEDI3250 (VN-0107) - Daiichi Sankyo 43

4.5 Comparative Efficacy and Safety of Pipeline Products 45

4.6 Product Competitiveness Framework 45

5 Clinical Trial Analysis 47

5.1 Failure Rate 47

5.1.1 Overall Failure Rate 47

5.1.2 Failure Rate by Phase and Molecule Type 48

5.1.3 Failure Rate by Phase and Molecular Target 49

5.2 Clinical Trial Duration 51

5.2.1 Clinical Trial Duration by Molecule Type 51

5.2.2 Clinical Trial Duration by Molecular Target 52

5.3 Clinical Trial Size 53

5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 53

5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 55

5.4 Competitive Clinical Trials Metrics Analysis 57 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.